Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base

Moving steadily with its 11-year long partnership with AstraZeneca PLC AZN, Myriad Genetics, Inc. MYGN recently announced the receipt of  FDA approval for using its BRACAnalysis CDx test to identify patients having a germline BRCA mutation (gBRCAm), suffering with advanced ovarian cancer and suitable for first-line maintenance therapy with AstraZeneca’s PARP (poly ADP ribose polymerase) inhibitor — Lynparza (olaparib) — following response to platinum-based chemotherapy.